Editas Medicine Inc (EDIT)

Schlusskurs vom Vortag:

$5.22

Offen:

$5.25

24-Stunden-Volumen:

1.35M

Marktkapitalisierung:

$437.49M

Einnahmen:

$78.12M

Nettoeinkommen (Verlust:

$-153.22M

KGV:

-1.7973

EPS:

-2.96

Netto-Cashflow:

$-136.90M

1W Leistung:

-3.10%

1M Leistung:

-26.32%

6M Leistung:

-18.28%

1J Leistung:

-32.66%

1-Tages-Spanne:

$5.1299

$5.395

52-Wochen-Spanne:

$5.11

$11.91

Editas Medicine Inc Stock (EDIT) Company Profile

Firmenname

Editas Medicine Inc

Sektor

Healthcare (1191)

Branche

Biotechnology (688)

Telefon

617-401-9000

Adresse

11 Hurley Street, Cambridge, MA

Mitarbeiter

112

Twitter

@editasmed

Nächster Verdiensttermin

2024-05-03

Neueste SEC-Einreichungen

EDIT's Discussions on Twitter

Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-06-12	Hochstufung	Raymond James	Mkt Perform → Outperform
2023-02-01	Eingeleitet	Cantor Fitzgerald	Overweight
2022-12-13	Eingeleitet	Citigroup	Neutral
2022-12-06	Fortgesetzt	Credit Suisse	Neutral
2022-11-18	Herabstufung	Credit Suisse	Outperform → Neutral
2022-11-18	Herabstufung	Oppenheimer	Outperform → Perform
2022-09-29	Eingeleitet	BofA Securities	Neutral
2021-10-19	Eingeleitet	SVB Leerink	Mkt Perform
2021-09-24	Eingeleitet	Stifel	Hold
2021-09-10	Hochstufung	Oppenheimer	Perform → Outperform
2021-08-09	Hochstufung	Truist	Hold → Buy
2021-08-05	Hochstufung	Evercore ISI	Underperform → Outperform
2021-06-04	Fortgesetzt	Robert W. Baird	Outperform
2021-05-04	Eingeleitet	RBC Capital Mkts	Sector Perform
2021-04-16	Eingeleitet	Goldman	Sell
2021-03-22	Eingeleitet	Credit Suisse	Outperform
2021-03-01	Herabstufung	Barclays	Overweight → Equal Weight
2021-02-26	Herabstufung	Truist	Buy → Hold
2021-01-19	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2021-01-07	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-12-10	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-11-03	Eingeleitet	Robert W. Baird	Underperform
2020-06-18	Fortgesetzt	SunTrust	Buy
2020-02-21	Eingeleitet	Wells Fargo	Equal Weight
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2018-10-10	Eingeleitet	Guggenheim	Neutral
2018-09-21	Eingeleitet	Raymond James	Outperform
2018-05-15	Bestätigt	Chardan Capital Markets	Buy
2018-02-13	Eingeleitet	CLSA	Underperform
2018-01-23	Hochstufung	SunTrust	Hold → Buy
2017-07-14	Eingeleitet	SunTrust	Hold
2017-03-28	Eingeleitet	Chardan Capital Markets	Buy
2016-08-10	Hochstufung	Jefferies	Hold → Buy
2016-06-02	Eingeleitet	Jefferies	Hold
2016-02-29	Eingeleitet	JMP Securities	Mkt Outperform
2016-02-29	Eingeleitet	JP Morgan	Neutral
2016-02-29	Eingeleitet	Morgan Stanley	Equal-Weight

Alle ansehen

Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten

Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know

Zacks Investment Research

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire Inc.

Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report?

Zacks Investment Research

1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.

The Motley Fool

1 Beaten-Down Stock With 55% Upside, According to Wall Street

The Motley Fool

Why Editas Medicine Stock Soared as Much as 42% Higher This Week

The Motley Fool

Finanzdaten der Editas Medicine Inc-Aktie (EDIT)

Editas Medicine Inc (EDIT) Umsatz 2024

Editas Medicine Inc (EDIT) Nettogewinn 2024

Editas Medicine Inc (EDIT) Free Cashflow 2024

Editas Medicine Inc (EDIT) Gewinn je Aktie 2024

Editas Medicine Inc-Aktie (EDIT) Insiderhandel